Eli Lilly, Nvidia to Build $1B AI Lab with Vera Rubin Chips
Eli Lilly will invest alongside Nvidia up to $1 billion over five years to build and equip a California AI research lab powered by Nvidia’s Vera Rubin processors. The joint facility will unite both companies’ scientists to generate new data and train AI models intended to accelerate drug discovery processes.
1. Nvidia and Eli Lilly Launch $1 Billion AI Co-Innovation Lab
Eli Lilly and Nvidia revealed plans to build and equip a joint research facility in California with a combined investment of up to $1 billion over five years. The lab will be powered by Nvidia’s latest Vera Rubin AI processors and staffed by a cross-company team of researchers. By pooling Lilly’s molecular and clinical data with Nvidia’s computational models, the partnership aims to accelerate target identification, virtual screening and lead optimization, potentially cutting months or years off traditional drug discovery timelines.
2. FDA Delay on Orforglipron Spurs Long-Term Buying Opportunity
Following the FDA’s decision to push Eli Lilly’s oral weight-loss candidate orforglipron into a second-quarter review window, the company’s shares dipped nearly 4%. Analysts, however, view this delay as temporary regulatory caution rather than a setback to the broader GLP-1 strategy. With Lilly carrying over $5 billion in cash and equivalents and a debt‐to‐capital ratio below 30%, long-term investors are positioned to capitalize on any pullbacks while the company expands manufacturing capacity ahead of launch.
3. Strong Q4 Outlook Driven by Mounjaro and Zepbound Demand
Eli Lilly expects fourth‐quarter revenue growth north of 50%, powered by global uptake of its GLP-1 therapies Mounjaro and Zepbound. Supply constraints that limited prescriptions earlier in the year have eased, and combined quarterly sales of these two products exceeded $10 billion in the most recent reporting period. While pricing pressures persist, volume gains and new market authorizations in Europe and Asia are projected to offset net price erosion by more than 200 basis points.
4. Retatrutide Phase 3 Data Highlight Dual Weight-Loss and Pain-Relief Benefits
In its latest phase 3 readout, Lilly’s next-generation triple agonist retatrutide delivered an average body-weight reduction of 28.7% at 68 weeks in obese patients—outperforming existing injectable GLP-1 standards. Remarkably, over 12% of participants with concurrent knee osteoarthritis reported complete resolution of joint pain, signaling potential label expansions into pain management. If approved, retatrutide could bolster Lilly’s obesity franchise beyond the current $20 billion annual sales run-rate projected by leading health‐economics models.